Filter By Year
June 22, 2023
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in JapanJune 06, 2023
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell LymphomaJune 05, 2023
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell LymphomaJune 01, 2023
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHAFebruary 22, 2023
Kite Completes Acquisition of TmunityFebruary 09, 2023
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaFebruary 02, 2023
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial ResultsFilter By Year